Clinical Trial Update: Raloxifene as an Adjuvant Treatment of the Negative Symptoms of Schizophrenia in Post-menopausal Women [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating raloxifene as an adjuvant treatment for negative symptoms in post-menopausal women with schizophrenia has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Raloxifene (raloxifene)

Snippet

Sponsor: Fundació Sant Joan de Déu | Conditions: Schizophrenia in Post Menopausal Women | Phase 3 | Status: COMPLETED